Skip to main content

Dr. Reddys Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access toCOVID-19 Treatment in India

academics

 

Clinical research courses

Dr. Reddys Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access toCOVID-19 Treatment in India

Dr. Reddys Laboratories Ltd announced that it has entered into a royalty-free, non-exclusive voluntary  licensing agreement with  Eli Lilly and Company for the manufacture and commercialization of the drug, baricitinib,in India.

The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment   of   suspected   or   laboratory   confirmed   COVID-19   in   hospitalized   adults   requiring supplemental  oxygen,  invasive  mechanical  ventilation,  or  extracorporeal  membrane  oxygenation (ECMO).

This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company’s existing range of COVID-19 therapeutics covering the full spectrum from mildtomoderate and severe conditions of the disease, anda vaccine.

Deepak Sapra, Chief Executive Officer, API and Services, Dr.Reddy’s Laboratories, said:"From the  start,  we  have  been determined  to  explore  every  possible avenueagainst  COVID-19.Our collaboration with Lilly will help us make yet anothertreatment option available to patients in India.”


<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email